Non-Hodgkin’s Lymphoma (NHL) is a cancer of the lymphatic system that develops from lymphocytes. Non-Hodgkin lymphoma can be further subdivided into more than 30 types depending on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). They can be further labeled as either aggressive (fast-growing) or indolent (slow-growing).
DelveInsight’s ‘Non-Hodgkin’s Lymphoma (NHL) Pipeline Insights’ report lays down a holistic coverage of the available therapies, Non-Hodgkin’s Lymphoma pipeline therapies in different phases of clinical development, key companies active in the NHL pipeline domain, drivers and barriers in the successful launch of the therapies and future trends.
Some of the notable pointers extracted from the Non-Hodgkin’s Lymphoma Pipeline report:
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight
The Non-Hodgkin’s Lymphoma Pipeline report offers insights into ongoing clinical trials, deals, mergers & acquisitions taking place in the Non-Hodgkin’s Lymphoma domain, recent approvals and failures in space, and growth prospects across the Non-Hodgkin’s Lymphoma domain.
Non-Hodgkin’s Lymphoma Pipeline Drugs
Drug
Company
Phase
MoA
RoA
Venetoclax
AbbVie
III
Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
Oral
Ibrutinib
Janssen
Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
Naratuximab emtansine
Debiopharm
II
Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerization inhibitors
Intravenous
NKTR-255
Nektar Therapeutics
Antibody-dependent cell cytotoxicity; Interleukin-15 receptor agonists
LOXO-305
Loxo Oncology
Agammaglobulinaemia tyrosine kinase inhibitors
LAM–002
AI Therapeutics
Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PIKFYVE protein inhibitors
CNCT19
Juventas Cell Therapy Ltd.
Immunologic cytotoxicity; T lymphocyte replacements
GB226
Genor Biopharma
Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
BI-1206
BioInvent International
I/II
Antibody-dependent cell cytotoxicity; Fc gamma receptor IIB antagonists; T lymphocyte stimulants
CAR-CD19 T Cells
Carsgen therapeutics
AUTO4
Autolus
TT11
Tessa Therapeutics
I
Pareneteral
CC-99282
Celgene
CRBN protein modulators; Ubiquitin protein ligase modulators
AB-205
Angiocrine Bioscience
Cell replacements
Request for Sample to know more @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight
Non-Hodgkin’s Lymphoma Therapeutics Assessment
The Non-Hodgkin’s Lymphoma Pipeline report proffers an integral view of the Non-Hodgkin’s Lymphoma emerging novel therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
Scope of the Non-Hodgkin’s Lymphoma Drug Pipeline Report
Coverage: Global
Key Players: Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, among others.
Key Non-Hodgkin’s Lymphoma Pipeline Therapies: Obinutuzumab, Abemaciclib, Ibrutinib, CPI 818, Devimistat, Venetoclax, Loncastuximab tesirine, Venetoclax, Loncastuximab tesirine, LAM-002, HMPL-523, Venetoclax, Ibrutinib, Naratuximab emtansine, NKTR-255, LOXO-305, LAM–002, CNCT19, GB226, BI-1206, CAR-CD19 T Cells, AUTO4, TT11, CC-99282, AB-205, and several others.
Discover more about the scope of the report @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight
Table of Contents
1
Report Introduction
2
Executive Summary
3
Non-Hodgkin’s Lymphoma Disease Overview
4
Non-Hodgkin’s Lymphoma Pipeline Therapeutics Comparative Analysis
5
6
In-depth Commercial Assessment
7
Non-Hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective
8
In-depth Commercial Non-Hodgkin’s Lymphoma Assessment
9
Non-Hodgkin’s Lymphoma Collaboration Deals
10
Late Stage Non-Hodgkin’s Lymphoma Products (Phase III)
11
Mid-Stage Non-Hodgkin’s Lymphoma Products (Phase II)
12
Early Stage Non-Hodgkin’s Lymphoma Products (Phase I)
13
Pre-clinical and Discovery Stage Non-Hodgkin’s Lymphoma Products
14
Inactive Non-Hodgkin’s Lymphoma Pipeline Products
Key Non-Hodgkin’s Lymphoma Products
16
Unmet Needs
17
Non-Hodgkin’s Lymphoma Market Drivers and Barriers
18
Future Perspectives and Conclusion
19
Analyst Views
20
Key Non-Hodgkin’s Lymphoma Companies
21
Appendix
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight